AIkido Pharma Announces Strategic Interest in ASP Isotopes Inc.

AIkido Pharma Inc. | December 07, 2021

AIkido Pharma Announces Strategic Interest in ASP Isotopes Inc.
AIkido Pharma Inc. announced that the Company secured a strategic equity interest in ASP Isotopes, Inc., which focuses on the non-nuclear supply of enriched isotopes.

ASP Isotopes' Aerodynamic Separation Process is a method of enriching molybdenum-100 which is a stable isotope of molybdenum. Technetium-99m is the most used radioisotope in the nuclear imaging industry, but the supply chain, which involves the radioactive decay of molybdenum-99 has been fraught with problems during the last 20 years. Mo-100 can be converted into Technetium-99m closer to the point of care thus eliminating the complex supply chain that currently exists and the risk of a supply interruption to the hospital and radiological pharmacy. ASP Isotopes is currently constructing a 20 Kg/year production plant in South Africa during 2021/22. There has been significant interest from potential customers for volumes exceeding 100% of the capacity of the first manufacturing plant. The company intends to enter into "take or pay" style offtake agreements with customers and by 2028, ASP Isotopes Inc intends to be a leading supplier of non-nuclear enriched isotopes generating over $150 million in EBITDA per annum.

 "The ASP Technology has been developed over the last 18 years. Following this capital raise, we believe that we are in a strong position to complete our first manufacturing plant for Molybdenun-100. Given the inherent challenging nature of the current supply chain, there has been considerable interest from potential customers, and we look forward to beginning commercial operations in the future. We would like to thank AIkido Pharma for their strategic investment in ASP Isotopes and we look forward to delivering extraordinary shareholder returns during the next several years".

Paul Mann, Chairman and CEO of ASP Isotopes 

Anthony Hayes, CEO of AIkido, noted, "This clearly exemplifies another high growth opportunity for us with a potential monetization event in the first half of 2022. ASP's unique technology, large market opportunity, notable investors and well accomplished management team are what initially attracted us to this opportunity. Our strategic investment in ASP Isotopes is exciting as they may have the best solution to help solve the current supply chain issue of a potential supply side shock with their Aerodynamic Separation Process. The Mo-99 market is currently estimated to be valued at $3.8 billion per year but with nine out of ten facilities expected to close within 10 years many governments and companies are exploring alternative methods of producing MO-99. We remain focused on continuing to acquire assets in our space that we believe will create shareholder value and possible monetization in the next 6-9 months."

About ASP Isotopes Inc.
ASP Isotopes Inc. was incorporated in 2021 and is an isotope enrichment company. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The company's first commercial product will be Molybdenum 100, which has the potential to replace Molybdenum 99, a commonly used product in the diagnostic imaging market.

About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus. Additionally, the Company has interests in high growth opportunities in diverse sectors with potential near term monetization events.


DNAtix intends to create a future ecosystem for Genetics where consumers, researchers, laboratories, and clinics operate making Genetics more accessible, transparent and anonymous. DNAtix intends to offer cutting-edge Genetics and Blockchain services which intend to be anonymous and encrypted and intends to include: analysis, storage and transfer of digitized DNA sequences through a Direct-to-Consumer platform (D2C).

Related News


Confo Therapeutics Enters Collaborative Agreement with Regeneron

Confo Therapeutics | December 01, 2021

Confo Therapeutics announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic antibody drug candidates. The agreement will leverage Confo’s expertise in addressing two GPCR targets for which functional antibodies are needed. Confo will be entitled to an upfront payment, research funding, and potential clinical, regulatory, and commercial payments. Further details regarding the agreement have not been disclosed. Confo’s ConfoBody-based technology platform aims to overcome the limitations of drug discovery on GPCRs, the largest and most diverse group of membrane receptors targeted by approximately 30% of all commercialized drugs. “With ten medicines approved by regulatory authorities, Regeneron is regarded in our industry as one of the most effective antibody discovery and development companies, with a successful track record of translating scientific insight into effective and innovative treatments. Working with them underscores the significant potential of our technology platform, in particular our new application to generate antibody drug candidates, and its promise to unveil GPCR drug targets and overcome a range of limitations of current approaches,” Cedric Ververken, Chief Executive Officer of Confo Therapeutics Christel Menet, Chief Scientific Officer of Confo Therapeutics added: “We value this opportunity to showcase the strength of this new addition to our technology suite and participate in what we hope will be the development of successful new antibody-based therapies. Parallel to this, we continue on our own drug development path, and drive innovative small molecule and biological therapeutics into our own pipeline.” About Confo Therapeutics Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs to uncover a wide range of previously inaccessible drug targets. This platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the vision of transforming therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. Confo Therapeutics was spun out of Vrije Universiteit Brussel and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium.

Read More

Grifols to acquire Montreal-based plasma fractionation facility and two purification facilities for US$460 million

Grifols, Green Cross Corporation | July 21, 2020

Grifols, a global healthcare company and one of world's top producers of plasma-derived medicines, today announced it has executed purchase arrangements with the South Korean-based GC Pharma (Group) whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of US$460 million. The transaction is part of Grifols' sustainable global growth strategy to expand plasma collection and fractionation capacity to ensure patients worldwide have safe and secure access to life-saving plasma-derived medicines. Most importantly, this strategic acquisition will strengthen Grifols' presence in Canada, building on a legacy of partnership in Canada's blood system. For more than three decades, Grifols has been a fractionator of Canadian plasma under contract manufacturing services, providing trusted plasma-derived medicines for Canadian patients and their healthcare providers. Throughout these many years Grifols has gained firsthand knowledge of the Canadian healthcare system. This transaction further demonstrates Grifols' commitment to supporting domestic self-sufficiency and security of plasma-protein-product supply.

Read More


Roivant Grows Computational Drug Discovery Engine with Acquisition of Silicon Therapeutics

Roivant Sciences | March 01, 2021

Silicon Therapeutics has assembled an exclusive industry-driving computational physics platform for the in silico design and optimization of small molecule drugs for testing disease targets. The platform incorporates custom strategies dependent on quantum mechanics, sub-atomic elements and measurable thermodynamics to beat basic bottlenecks in drug disclosure projects, for example, anticipating restricting energies and conformational conduct of molecules. Silicon Therapeutics' computational platform is controlled by a restrictive supercomputing group and custom equipment empowering exact all-molecule reenactments at organically important timescales. This computational platform is firmly incorporated with experimental laboratories equipped for biophysics, medical chemistry and biology to encourage the quick movement of drug applicants by expanding recreations with biophysical data. The organization has utilized these abilities to find numerous drug applicants. The procurement of Silicon Therapeutics supports and supplements Roivant's focused on protein debasement platform. That platform will be fueled by VantAI's high level AI models prepared on restrictive degrader-explicit experimental data and by Silicon Therapeutics' exclusive computational physics abilities, which help address a large number of the methodology explicit difficulties of degrader design and optimization. Coordinating Silicon Therapeutics and VantAI will empower Roivant to particularly catch the force of both computational physics and AI based ways to deal with drug design; for example, by joining exclusive computational physics reproductions as preparing data for VantAI's degrader-explicit profound learning models. "The combination of Silicon Therapeutics' integrated approach, platform and highly capable team with Roivant's technologies and commitment to transforming the pharmaceutical industry represents a new and exciting paradigm in drug discovery and development," said Roger Pomerantz, M.D., F.A.C.P., chairman of the board of directors of Silicon Therapeutics. About Roivant Sciences Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants – nimble and focused biopharmaceutical and health technology companies.

Read More


DNAtix intends to create a future ecosystem for Genetics where consumers, researchers, laboratories, and clinics operate making Genetics more accessible, transparent and anonymous. DNAtix intends to offer cutting-edge Genetics and Blockchain services which intend to be anonymous and encrypted and intends to include: analysis, storage and transfer of digitized DNA sequences through a Direct-to-Consumer platform (D2C).